Arcus Biosciences, Inc. Sale of Stock, Consideration Received on Transaction
Arcus Biosciences, Inc. (RCUS) reported Sale of Stock, Consideration Received on Transaction of $288.00 million for the 3-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-05
- Arcus Biosciences, Inc. sale of stock, consideration received on transaction for the quarter ending 2025-12-31 was $288.00M.
- Arcus Biosciences, Inc. sale of stock, consideration received on transaction for the quarter ending 2025-03-31 was $150.00M.
| Period end | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month |
|---|---|---|
| 2025-12-31 | $288.00M 10-K · filed 2026-02-25 | |
| 2025-03-31 | $150.00M 10-Q · filed 2026-08-05 | |
| 2025-02-28 | $150.00M 10-Q · filed 2025-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |